Results 21 to 30 of about 15,148 (196)

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

BMC Cancer, 2021
Background Contradictory and limited data are available about the presentation and outcomes of patients with RET-fusion positive metastatic NSCLC as compared to patients without RET fusions.
Lisa M. Hess, Yimei Han, Yajun Emily Zhu, Naleen Raj Bhandari, Anthony Sireci   +4 more
doaj   +1 more source

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report

JTO Clinical and Research Reports, 2022
Introduction: RET is well known as an important driver gene in NSCLC. Moreover, RET is a rare acquired resistance mechanism to EGFR-mutant NSCLC. Only 36 NSCLC cases of coexistence of EGFR and RET were reported previously worldwide.
Zichen Zhao, MD, Chao Su, PhD, Weigang Xiu, MD, Weiya Wang, MD, Shasha Zeng, MD, Meijuan Huang, MD, Youling Gong, MD, You Lu, MD, PhD, Yan Zhang, MD, PhD   +8 more
doaj   +1 more source

Genomic landscape of 891 RET fusions detected across diverse solid tumor types

npj Precision Oncology, 2023
In this study, we report the clinicopathologic and genomic profiles of 891 patients with RET fusion driven advanced solid tumors. All patient samples were tested using a tissue-based DNA hybrid capture next generation sequencing (NGS) assay and a subset ...
Vamsi Parimi, Khaled Tolba, Natalie Danziger, Zheng Kuang, Daokun Sun, Douglas I. Lin, Matthew C. Hiemenz, Alexa B. Schrock, Jeffrey S. Ross, Geoffrey R. Oxnard, Richard S. P. Huang   +10 more
doaj   +1 more source

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Frontiers in Oncology, 2022
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status.
Lu Zhao, Lu Zhao, Qingyun Mei, Qingyun Mei, Yongchao Yu, Yongchao Yu, Na Wang, Na Wang, Dou Zhang, Dou Zhang, Dongying Liao, Dongying Liao, Jinhui Zuo, Jinhui Zuo, Hongxia Xie, Hongxia Xie, Yingjie Jia, Yingjie Jia, Fanming Kong, Fanming Kong   +19 more
doaj   +1 more source

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

Frontiers in Oncology, 2022
Patients with RET fusions represent 1-2% of all cases of non-small cell lung cancer (NSCLC), the majority of whom are younger, and are extremely rare in the elderly.
Li An, Pengzhi Chen, Junfeng Wang, Xuebing Qin, Tingting Liu, Yanhong Gao, Peng Wang, Dong Zhang, Xiangqun Fang, Zhijian Zhang   +9 more
doaj   +1 more source

The relationship between genetic characteristics and clinical characteristics and the efficacy of 131I therapy in children and adolescents with locally advanced or metastatic differentiated thyroid cancer [PDF]

Zhongguo aizheng zazhi, 2022
Background and purpose: The molecular characteristics of differentiated thyroid cancer (DTC) in children and adolescents and its role in clinical practice remain unclear.
SUN Di, SUN Yuqing, ZHANG Xin, HUANG Lisha, LIN Yansong
doaj   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China

Thoracic Cancer, 2023
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell‐surface molecules responsible for transmitting signals that regulate cell growth and differentiation.
Xingxiang Pu, Chunwei Xu, Qian Wang, Wenxian Wang, Fang Wu, Xiuyu Cai, Zhengbo Song, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Gen Lin, Long Huang, Jingping Yuan, Zhansheng Jiang, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Xuewen Liu, Jingxun Wu, Jin Zhou, Zhengfei Zhu, Weiwei Pan, Fei Pang, Jintao Huang, Kai Wang, Fan Wu, Tingting Shen, Shirui Zou, Bingwei Xu, Liping Wang, Youcai Zhu, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jing Kang, Jiatao Zhang, Chao Zhang, Jianfei Fu, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Yue Hao, Zhen Wang, Bing Wan, Donglai Lv, Gang Lan, Shengjie Yang, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Yuan Li, Zhefeng Liu, Nong Yang, Huijuan Wang, Wenbin Huang, Zhuan Hong, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Xixu Zhu, Yi Shen, Yiping Zhang, Shenglin Ma, Yong Song, Yuanzhi Lu, Wenfeng Fang, Ziming Li, Lin Wu   +102 more
doaj   +1 more source

Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report

Frontiers in Oncology
IntroductionApproximately 1−2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and ...
Urpo Kiiskinen, Grace Segall, Hollie Bailey, Cameron Forshaw, Tarun Puri   +4 more
doaj   +1 more source

Significances of RET Fusion Gene in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2013
Lung cancer is the leading cause of cancer-related death worldwide, molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment.
Jingjing LIU, Minghong BI
doaj   +1 more source